HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 and Recommendations Made By the NCPE in Ireland
Abstract
Authors
A. Assi T. Karbanova L. Alghawas Y.X.D. Lim L. Trela-Larsen C. Usher M. Barry C. Walsh